Cyclenium Pharma and Fundación MEDINA Announce Drug Discovery and Collaboration Agreement
Cyclenium Pharma Inc. and Fundación MEDINA (Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, the University of Granada and Merck Sharp and Dohme de España S.A., announced the signing of a drug discovery and collaboration agreement. The collaboration will utilize Cyclenium’s proprietary QUEST Library™ of next generation macrocyclic molecules and associated hit-to-clinical candidate optimization capabilities in concert with the extensive expertise and experience of Fundación MEDINA in infective disease research. The objective of the collaboration is to discover new anti-infective drug candidates effective against a number of clinically important bacterial and fungal pathogens. For Cyclenium, this is the fourth discovery collaboration established over the past year.
Other news from the department science
